A comprehensive view of astrazeneca ab. This page highlights a small sample of our full coverage.
For real-time access, please log in to your Health Care Sector Market Intelligence Service.

Recent Articles

sample of recent headlines, press releases and get more..

AstraZeneca's Ultomiris approved in Japan for long-acting treatment of anti-aquaporin-4 antibody-positive neuromyelitis optica spectrum disorder, including neuromyelitis optica; drug offers potential for relapse elimination with dosing every eight weeks
Published: May 30, 2023 by PharmaTimes
INTERNATIONAL PATENT: ASTRAZENECA UK LIMITED, DAIICHI SANKYO COMPANY, LIMITED FILES APPLICATION FOR "COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR"
Published: May 30, 2023 by U.S. Fed News
Australia Patent: DAIICHI SANKYO, ASTRAZENECA UK File Application for 'COMBINATION OF ANTIBODY-DRUG CONJUGATE AND PARP1 SELECTIVE INHIBITOR'
Published: May 26, 2023 by Australian Government
AstraZeneca to highlight practice-changing cancer medicines in its pipeline at ASCO 2023; over 130 abstracts will feature 22 approved and potential new medicines
Published: May 25, 2023 by AstraZeneca AB
US Patent Issued to AstraZeneca on May 23 for "Certain (2S)-N-[(1 s)-1-cyano-2-phenylethyl-1,4-oxazepane-2-carboxamides as dipeptidyl peptidase 1 inhibitors" (British, Swedish Inventors)
Published: May 24, 2023 by U.S. Fed News

Ask us about our Health Care Sector market view

Trending Chart

Interactive chart with headline count